



Prophylaxis in Patients with Von Willebrand Disease: Expert Perspectives and Shared Experiences

Robert Sidonio, Jr., MD

Associate Director
Hemostasis and Thrombosis
Emory University
Atlanta, Georgia

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Director, Clinical Research Center
McGovern Medical School
The University of Texas Health Science Center
Houston, Texas

Angela C. Weyand, MD

Clinical Assistant Professor
Pediatrics - Hematology/Oncology
University of Michigan, Ann Arbor
Ann Arbor, Michigan

Faculty Disclosures

- **Dr. Robert Sidonio, Jr.** has relevant financial relationships related to consulting from Bayer AG, Genentech, Inc., Grifols S.A., Guardian Therapeutics, Novo Nordisk A/S, Octapharma USA, Inc., Sanofi, Sobi, and Takeda Oncology, as well as investigator sponsored studies from Genentech, Octapharma, and Takeda.
- **Dr. Miguel Escobar** has relevant financial relationships related to advisory activities from CSL Behring, Genentech - A Member of the Roche Group, HEMA Biologics, LLC, LFB Biopharmaceuticals Limited, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Oncology, and uniQure N.V., as well as consulting from HEMA Biologics and LFB. He is on the speakers' bureau for Bayer AG, BioMarin Pharmaceutical Inc., and Kedrion, and has received research grant(s) from Genentech - A Member of the Roche Group, Novo Nordisk A/S, Sanofi, Takeda, and uniQure.
- **Dr. Angela Weyand** has relevant financial relationships related to consulting from Bayer AG, Genentech - A Member of the Roche Group, Sanofi, and Takeda Oncology. She has received research grant(s) from Novo Nordisk A/S, Pfizer Inc., Sanofi, and Takeda.

Learning Objectives

- Outline recent guidelines concerning the use of short- and long-term prophylaxis in patients with von Willebrand Disease (VWD)
- Identify patient and disease characteristics that suggests a patient with VWD will benefit from long-term prophylaxis
- Summarize the safety and efficacy data from recent and ongoing trials investigating novel prophylaxis agents for VWD
- Outline factors that must be considered when identifying therapeutic strategies, doses and regimens for prophylaxis in patients with VWD